← Back to Search

Cannabidiol for Seizures

Phase 3
Recruiting
Research Sponsored by GW Research Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants who have uncontrolled seizures, and who are currently receiving 1 or more antiseizure medication (ASMs)
Participants with TSC must have a diagnosis per the 2012 International Tuberous Sclerosis Complex Consensus Conference
Must not have
Has significantly impaired hepatic function prior to Visit 3
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at day 1 (visit 3), day 169 (visit 13), and day 365 (eot)
Awards & highlights

Summary

This trial tests a medication called GWP42003-P in children under 2 years old who have severe seizure disorders like TSC, LGS, or DS. The study will last over a year and will check if the medication is safe, how it moves through the body, and if it helps reduce seizures. These conditions often don't respond well to usual treatments, so new options are needed. Cannabidiol (pharmaceutical) is approved by the FDA for the treatment of seizures associated with DS, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients ≥1 year of age.

Who is the study for?
This trial is for children under 2 years old with TSC, LGS, or DS who have seizures not well-controlled by current medications. They must be diagnosed according to specific guidelines and their caregivers should consent and comply with study requirements. Children with certain health issues or hypersensitivity to cannabinoids are excluded.
What is being tested?
The trial tests GWP42003-P, a cannabidiol oral solution as an additional treatment for young children with TSC, LGS, or DS experiencing poorly controlled seizures. It aims to assess the safety, how the body processes the drug (pharmacokinetics), and its effectiveness.
What are the potential side effects?
Potential side effects of GWP42003-P may include sleepiness, decreased appetite, diarrhea, fever, vomiting and fatigue. Since it contains cannabidiol derived from cannabis plants there might also be risks related to mood changes or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have seizures that aren't controlled even though I'm on medication.
Select...
I have been diagnosed with Tuberous Sclerosis Complex according to the 2012 guidelines.
Select...
My seizures are not fully controlled by my current medication.
Select...
My child is between 1 month and 2 years old and has TSC, DS, or LGS.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My liver is not working well.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at day 1 (visit 3), day 169 (visit 13), and day 365 (eot)
This trial's timeline: 3 weeks for screening, Varies for treatment, and at day 1 (visit 3), day 169 (visit 13), and day 365 (eot) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinician Global Impression of Change/Severity (CGIC/S) Score
Infant and Toddler Quality of Life Questionnaire Short Form 47 (ITQOL-47) Score
Secondary study objectives
Number of Treatment Responders
Percentage Change from Baseline in Total Countable Seizures

Side effects data

From 2016 Phase 3 trial • 225 Patients • NCT02224560
30%
Somnolence
26%
Decreased appetite
15%
Diarrhoea
12%
Upper respiratory tract infection
12%
Vomiting
11%
Pyrexia
11%
Nasopharyngitis
10%
Fatigue
6%
Headache
6%
Convulsion
6%
Lethargy
5%
Status epilepticus
5%
Insomnia
5%
Irritability
2%
Pneumonia
1%
Lymphopenia
1%
Constipation
1%
Pneumatosis intestinalis
1%
Adenovirus infection
1%
Pneumonia mycoplasmal
1%
Respiratory syncytial virus infection
1%
Delayed recovery from anaesthesia
1%
Aspartate aminotransferase increased
1%
Alanine aminotransferase increased
1%
Gamma-glutamyltransferase increased
1%
Pleural effusion
1%
Device malfunction
1%
Hypotension
100%
80%
60%
40%
20%
0%
Study treatment Arm
GWP42003-P 20 mg/kg/Day Dose-Safety Analysis Set
Placebo-Safety Analysis Set
GWP42003-P 10 mg/kg/Day Dose-Safety Analysis Set

Trial Design

1Treatment groups
Experimental Treatment
Group I: GWP42003-PExperimental Treatment1 Intervention
The 52-week treatment period includes a fixed 2-week titration schedule followed by flexible dose optimization. Day 1: 5 mg/kg/day (2.5 mg/kg twice daily (b.i.d.)) Day 8: 10 mg/kg/day (5 mg/kg b.i.d.) Day 15 to Week 52: Flexible dosing based on the participant's observed efficacy, safety, and tolerability per the investigator's clinical judgement. Up to a maximum of 20 mg/kg/day (10 mg/kg b.i.d.) for LGS and DS or 25 mg/kg/day (12.5 mg/kg b.i.d.) for TSC, in maximum weekly increments of 5 mg/kg/day (≤ 2.5 mg/kg b.i.d.).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GWP42003-P
2016
Completed Phase 3
~1740

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Tuberous Sclerosis Complex (TSC) often involve modulation of the endocannabinoid system, anti-inflammatory properties, and potential neuroprotective effects, as seen with Cannabidiol (CBD). CBD modulates the endocannabinoid system, which helps regulate pain, mood, and memory, and has anti-inflammatory properties that reduce neuroinflammation. Additionally, its neuroprotective effects may protect against neuronal damage and improve brain function. These mechanisms are crucial for TSC patients who experience seizures and other neurological symptoms, offering a comprehensive approach to symptom management.
Impact of Endocannabinoid System Manipulation on Neurodevelopmental Processes Relevant to Schizophrenia.Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway.Hippocampal mammalian target of rapamycin is implicated in stress-coping behavior induced by cannabidiol in the forced swim test.

Find a Location

Who is running the clinical trial?

GW Research LtdLead Sponsor
35 Previous Clinical Trials
3,198 Total Patients Enrolled
Jazz PharmaceuticalsLead Sponsor
249 Previous Clinical Trials
34,814 Total Patients Enrolled

Media Library

GWP42003-P Clinical Trial Eligibility Overview. Trial Name: NCT04485104 — Phase 3
Tuberous Sclerosis Complex Research Study Groups: GWP42003-P
Tuberous Sclerosis Complex Clinical Trial 2023: GWP42003-P Highlights & Side Effects. Trial Name: NCT04485104 — Phase 3
GWP42003-P 2023 Treatment Timeline for Medical Study. Trial Name: NCT04485104 — Phase 3
~2 spots leftby Jan 2025